About Third Wave Technologies
Third Wave Technologies is a company based in Xiamen (China) founded in 1993 was acquired by Hologic in June 2008. Third Wave Technologies has raised $19.3 million across 3 funding rounds from investors including Hologic and Deerfield Triarc Capital. Third Wave Technologies operates in a competitive market with competitors including ArcherDX, Biofidelity, Auxogyn, NuProbe and Overture Life, among others.
- Headquarter Xiamen, China
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Third Wave Technologies
Third Wave Technologies has successfully raised a total of $19.3M across 3 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $25 million completed in December 2007. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Third Wave Technologies
Third Wave Technologies has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Hologic and Deerfield Triarc Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Provides asset management and investment advisory services.
|
Locked | Locked | Locked | |
|
Diagnostic and surgical products for women's healthcare are provided.
|
Locked | Locked | Locked |
Investor details for Third Wave Technologies
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Third Wave Technologies
Investment portfolio details for Third Wave Technologies
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Third Wave Technologies
Detailed financials for Third Wave Technologies
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Third Wave Technologies Comparisons
Peer comparison for Third Wave Technologies
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Third Wave Technologies
Third Wave Technologies operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ArcherDX, Biofidelity, Auxogyn, NuProbe and Overture Life, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| Locked | Locked | Locked |
Molecular diagnostic assays are developed for target DNA sequence detection.
|
|
| Locked | Locked | Locked |
Diagnostic technologies for IVF embryo viability assessment are developed.
|
|
| Locked | Locked | Locked |
Sensitive multiplex platforms for QPCR are developed using toehold probes.
|
|
| Locked | Locked | Locked |
Embryology diagnosis devices are developed for medical professionals.
|
|
| Locked | Locked | Locked |
Nucleic acid drugs are developed via RNA interference technology.
|
Detailed competitors of Third Wave Technologies
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Third Wave Technologies
Complete news archive for Third Wave Technologies
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Third Wave Technologies
Third Wave Technologies was founded in 1993 and raised its 1st funding round 6 years after it was founded.
Third Wave Technologies is headquartered in Xiamen, China. It is registered at Xiamen, Fujian, China.
Third Wave Technologies is a funded company, having raised a total of $19.3M across 3 funding rounds to date.
Third Wave Technologies was founded in 1993 and is based in Xiamen, China, as part of Hologic. Molecular diagnostic products are developed and marketed for DNA and RNA analysis in healthcare applications. Tools for disease detection and treatment are supplied to physicians and researchers. In vitro diagnostic devices and analyte specific reagents are offered, supporting assays for hepatitis C virus genotyping and inherited disorders testing.
Third Wave Technologies's top competitors include Overture Life, ArcherDX and NuProbe.
Third Wave Technologies has 2 investors. Key investors include Hologic, and Deerfield Triarc Capital.